Emory University Portfolio holdings
Top Buys
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.6M |
| 2 |
LPL Financial
LPLA
|
+$1.57M |
| 3 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$1.54M |
| 4 |
QVCGA
QVC Group Inc Series A
QVCGA
|
+$1.52M |
| 5 |
Liberty Media Series C
FWONK
|
+$1.51M |
Top Sells
| 1 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$1.05M |
| 2 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
+$961K |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$886K |
Sector Composition
| 1 | Healthcare | 13.26% |
| 2 | Consumer Discretionary | 5.78% |
| 3 | Financials | 4.41% |
| 4 | Energy | 3.47% |
| 5 | Technology | 1.96% |
Similar funds
Emory University's Q2 2015 Portfolio in Review
As of Q2 2015, Emory University held 24 positions worth $73.9M, up 40% from $52.9M the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Emory University deployed $20M of net new capital in Q2 2015, opening 14 new positions and adding to 6 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 9,279 shares worth $1.68M.
By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the most notable exit was Bellicum Pharmaceuticals, Inc., an estimated $1.05M sold.
- Emory University's largest Q2 2015 buy was Alexion Pharmaceuticals: 9,279 shares worth $1.68M.
- Emory University added most to Genomic Health, Inc. in Q2 2015, an estimated $643K increase.
- Emory University fully exited Bellicum Pharmaceuticals, Inc. in Q2 2015, selling an estimated $1.05M.
- Emory University's ten largest holdings make up 79% of its $73.9M portfolio in Q2 2015.
- Emory University opened 14 new positions and closed 3 in Q2 2015.
- Emory University's portfolio value rose 40% quarter-over-quarter to $73.9M.
Based on Emory University's 13F filing for Q2 2015, filed 13 Aug 2015.